to-BBB has entered into a research collaboration with Genzyme to evaluate to-BBB’s proprietary G-Technology to safely enhance delivery of biologics for neurodegenerative diseases.
G-Technology is designed to transport different classes of drugs across the blood-brain barrier by formulating these drugs into proprietary glutathione coated liposomes.
The collaboration with to-BBB could provide Genzyme with an opportunity to improve brain delivery of biological treatments to improve the lives of patients with brain disease.
Geoff McDonough, senior vice president of Genzyme, said: “This collaboration will explore an essential component of our work to deliver therapies to the brain, and could further our commitment to patients with neuronopathic disease.”
Willem van Weperen, CEO of to-BBB, said: “We look forward to collaborating with Genzyme.” Combining the expertise of Genzyme in neurodegenerative diseases with to-BBB’s brain delivery knowledge, should lead to further progress in treating patients with brain diseases with biological drugs.”